Lemonade's profitability problem outweighs its impressive growth. Revenue rose from $23 million in 2018 to $975 million over the last 12 months, a 65% CAGR, and members nearly tripled since 2021. Yet the capital-light insurtech still guides to negative 2026 EBITDA, below its initial expectations, and after 11 years is not close to positive EBITDA. Management has been less transparent about cutting costs. Solving profitability could make it a home run; Root's management is preferred. x.com  x.com  … Show more

Lemonade is reducing transparency on a key indicator of whether it can scale efficiently. Earnings reports once showed in-force premium versus opex, then switched to premium versus employee count, presumably as opex rose, and now show premium alone. Investors are tiring of waiting for EBITDA profitability, and the missing comparative metrics give less insight into how Lemonade gets there. The stock had run ahead into earnings, so a reset was due without a blowout. x.com  x.com 

Lemonade's business thesis has not broken; the stock is falling on normal high-beta behavior, not fundamentals. With beta over two, high short interest and no profits yet, it moves sharply with risk appetite. Co-founder Daniel Schreiber's share sales are normal for a founder with concentrated wealth, though their framing was tone deaf, and stock pay is needed to hire engineers against Google and Meta. Long-term holders should watch in-force premium growth, loss ratio and operating leverage. … Show more

Root looks cheap at about 7x earnings while buying back shares, with proven fully loaded economics. Even after $25.3 million of sales and marketing and $32 million of partner acquisition costs, it earned $25 million of GAAP profit with a 92.1% combined ratio. Lemonade grows much faster and may have more upside if retention and cross-sell deliver, but its case rests on modeled lifetime value and its shareholders keep getting diluted. Root's premium volume is roughly flat to down. x.com  x.com  … Show more

Lemonade looks good but not good enough after a lofty price and high expectations into earnings, so it needs to get cheaper before it is worth buying. In-force premium grew 32% and revenue 79% as it approaches positive cash flow by the end of 2026; the low $40s or $30s would be the level to buy more. x.com  x.com 

Lemonade's share-price drop after a great second quarter is a wild overreaction. Per its Q2 2026 results, in-force premium rose 32.4% to $1.43 billion and revenue grew 79% to $294 million, the 11th straight quarter of accelerating growth, with over 3.3 million customers. x.com  x.com 

Lemonade looks expensive once valued as what it is, an insurance company. Replying to @javierluraschi's post on the stock, any price above 1x revenue is expensive for an insurer. x.com 

Lemonade will likely fall back below $60 again, as it usually does, because it does not expect to be profitable until late 2027–2028, which keeps the stock volatile for a while. x.com 

Lemonade is a monster stock in the making after a massive quarter. Per co-founder @shai_wininger, in-force premium grew 32% to $1.33 billion, the 10th straight quarter of acceleration, revenue rose 71% to $258M and gross profit 159% to $100M, with $17M of adjusted free cash flow. Pet passed $500M of premium, car grew 60% with its loss ratio down 14 points to 74%, and Lemonade raised 2026 guidance, targeting positive adjusted EBITDA in Q4. x.com 

Blend Labs is unappealing because its business shows stalling growth, growing churn and a shrinking cash pile. The chart is a falling knife without signs of life, and Lemonade is the better place to stay than adding Blend. x.com